Clinical Trial Search

Phase 3 N=8,057 Study of a Single Intramuscular Dose of Nirsevimab in the Prevention of Hospitalizations Due to Respiratory Syncytial Virus (RSV) Infection in Healthy Term and Preterm Infants During the First Year of Life

RSV Immunization · Healthy Volunteer

Primary: Number of Participants With Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Infection (LRTI) Hospitalization Through the Respiratory Syncytial Virus Season…

Sanofi Pasteur, a Sanofi Company Results Apr 2025 6.0% serious AE View details

Phase 3 N=176 Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP)

Palmoplantar Pustulosis

Primary: Percentage of Participants Who Achieved at Least a 50% Reduction From Baseline in Palmoplantar Pustulosis Area and Severity Index (PPPASI) Total Score (PPPASI-50) at…

Amgen Results Apr 2025 3.1% serious AE View details

Phase 3 N=670 Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia

Community-acquired Pneumonia · Bacterial Pneumonia

Primary: Percentage of Participants With Early Clinical Response at the Early Clinical Response (ECR) Visit — 89.6; 87.7; 8.6; 9.3 Percentage of participants

Paratek Pharmaceuticals Inc Results Apr 2025 4.8% serious AE View details

Phase 3 N=49 Preloading With Nicotine Replacement Therapy in HIV-positive Smokers to Improve Self-Efficacy and Quit Attempts

Tobacco Use Cessation

Primary: Adherence to NRT — 47.4; 32.7 days of NRT use

Brown University Results Apr 2025 0.0% serious AE View details

Phase 3 N=286 Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)

Hepatitis C Virus (HCV)

Primary: Percentage of Participants Achieving Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in the Intention-to-Treat (ITT) Population — 96.2 percentage of…

AbbVie Results Apr 2025 4.2% serious AE View details

Phase 3 N=1,402 A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)

Melanoma

Primary: Recurrence-Free Survival (RFS) — NA; NA Months

Merck Sharp & Dohme LLC Results Apr 2025 11.9% serious AE View details

Phase 3 N=316 Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness

Motion Sickness

Primary: Prevention of Vomiting Measured by Vomiting Assessment (VA) — 11; 19; 40 Participants

Vanda Pharmaceuticals Results Apr 2025 0.0% serious AE View details

Phase 3 N=549 ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease

Alzheimer Disease · Dementia of Alzheimer Type

Primary: Global Statistical Test (GST) Score — -0.126; -0.208 Z-score

LeonaBio Results Apr 2025 5.3% serious AE View details

Phase 3 N=108 Sodium Oxybate in Spasmodic Dysphonia and Voice Tremor

Spasmodic Dysphonia · Voice Tremor

Primary: Symptom Severity — 28.0; 18.6; 14.2; 12.3 score on a scale — p=0.01

Kristina Simonyan Results Apr 2025 0.0% serious AE View details

Phase 3 N=1,291 A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec

Diabetes Mellitus, Type 2

Primary: Change in Glycated Haemoglobin (HbA1c) — -1.60; -0.90 Percentage point of HbA1c — p=<0.0001

Novo Nordisk A/S Results Apr 2025 9.9% serious AE View details

Phase 3 N=150 Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity

Obesity

Primary: Change in Body Weight (%) : In-trial Observation Period — -16.4; -2.6 Percentage of body weight — p=<0.0001

Novo Nordisk A/S Results Apr 2025 11.3% serious AE View details

Phase 3 N=746 A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease

Colitis, Ulcerative · Crohn's Disease

Primary: Number of Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs Adjusted by Duration of Participant's Exposure to Long-term Vedolizumab Treatment — 22.9; 28.0…

Takeda Results Apr 2025 24.9% serious AE View details

Phase 3 N=24 Targeting the Endothelial Glycocalyx to Enhance Vascular Function and Exercise-Induced Vascular Adaptations in Type 2 Diabetes

Diabetes Mellitus, Type 2

Primary: Glygocalyx Integrity - Perfused Boundary Region — 0.11; -0.16 Delta micrometers (mcm)

VA Office of Research and Development Results Apr 2025 0.0% serious AE View details

Phase 3 N=555 Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen

Seasonal Allergic Rhinitis · Rhinoconjunctivitis

Primary: Combined Symptom and Medication Score (CSMS) Averaged Over the Peak Grass Pollen Season (GPS) — 1.08; 1.34 score on a scale — p=0.00048

Allergy Therapeutics Results Apr 2025 1.4% serious AE View details

Phase 3 N=447 To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes

Glaucoma, Open-Angle · Ocular Hypertension

Primary: Mean Change in Intra-ocular Pressure — -5.30; -5.16; -6.92; -6.57 mmHG

Padagis LLC Results Apr 2025 1.3% serious AE View details